Pay in 4 interest-free payments of $5.42 Learn more
Ships within 48 hours · Estimated delivery Jul 31 - Aug 5
The evidence positions NNMT as an active participant in the metabolic changes seen in obesity
This is a genuine gap in the literature, and clinicians typically default to injectable routes when the target tissue is outside the gastrointestinal tract
Results were not statistically significant for weight loss compared to placebo
Apr 29, 2025, 08:00 ET All doses of FDA-approved Wegovy , the most widely prescribed and studied GLP-1 for weight loss, are now accessible to patients of select telehealth providers via simplified pathway to NovoCare Pharmacy Providers include Hims & Hers Health, Inc., LifeMD, and Ro Wegovy is in full supply, and patients in the US can access authentic, FDA-approved Wegovy in a high-quality premium pen for $499 per month Novo Nordisk continues to explore new pathways to conveniently and affordably connect people living with obesity to Wegovy PLAINSBORO, N.J., April 29, 2025 /PRNewswire/ -- Today, Novo Nordisk announced it is expanding patient access to Wegovy (semaglutide) injection 2.4 mg by enabling select telehealth providers to work directly through NovoCare Pharmacy to offer a simplified pathway for self-paying patients seeking access to authentic, FDA-approved Wegovy
/assets/images/provider/photos/2798511.png)
US$ 22.79
US$ 29.71
US$ 25.48
